Roles
- Associate Professor of Clinical Medicine
-
Biography
Namrata S. Chandhok, MD, MS is an Associate Professor of Clinical Medicine in the Division of Hematology at the University of Miami Miller School of Medicine and a hematologist-oncologist at Sylvester Comprehensive Cancer Center. She serves as Medical Director of Hematology and Oncology at University of Miami Hospital and as the clinical leader of the leukemia site disease group.
Dr. Chandhok specializes in the care of patients with acute myeloid leukemia, myelodysplastic syndromes, and other myeloid malignancies. Her research focuses on translating advances in myeloid biology into clinical trials, with particular interests in clonal hematopoiesis, cancer prevention, treatment-related toxicity, and digital health. She is also committed to improving equity and access in cancer clinical trials.
Dr. Chandhok received her medical degree from George Washington University, completed residency at Tufts Medical Center, and fellowship training in Hematology and Medical Oncology at Yale University. She holds a master’s degree in clinical Investigation from the University of Miami. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Emerging Leaders: Preparing Cancer Researchers for Professional Success
Kickstarting Cancer Research Pathways for Next-Gen Scientists
Mentoring the Next Generation in Blood Cancer Research
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 11 clinical trials.
-
To assess the safety and tolerability of IV-administered CLN-049. To characterize select PK parameters associated with IV-administered CLN-049.
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase I
- Enrollment Status: Open
-
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase 1
- Enrollment Status: Open
-
A Phase II Clinical Trial of E7820 for Patients With Relapsed/Refractory Myeloid Malignancies With Mutations in Splicing Factor Genes.
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase 2
- Enrollment Status: Closed
-
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase I
- Enrollment Status: Closed
-
To evaluate the length of time until development of a myeloid neoplasm (ie MDS, MPN, CMML, or AML) in high-risk CCUS patients receiving canakinumab as therapeutic intervention compared to the control arm. Time to overt myeloid malignancy (MDS, MPN, CMML, and AML) defined from the date of randomization until the first date of overt myeloid malignancy diagnosis. Patients without a myeloid malignancy diagnosis will be censored at date of last follow-up.
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase II
- Enrollment Status: Open
-
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase 1
- Enrollment Status: Closed
-
Estimate the CR rate in subjects with newly diagnosed AML with p-HMA receiving tagraxofusp and azacitidine with venetoclax .
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase II
- Enrollment Status: Open
-
The purpose of this study is to collect clinical data for research purposes, from participants diagnosed with leukemia . The information gathered will contribute our understanding of how patients undergoing leukemia treatment, interact with a consumer wearable device, like FITBIT Charge 6, and My Wellness Research software application, designed for reporting how they feel during treatment. We will also investigate if the data we gather can be used to alert your doctor if they may be getting ill.
- Principal Investigator: Namrata Chandhok
- Study Phase: Pilot/Feasibility
- Enrollment Status: Not Accepting
-
Overall, the goal of this research study is to determine if tagraxofusp (Tag) in combination with venetoclax (Ven) and azacitidine (Aza) can safely treat cancer in participants who have not received treatment for their AML before (i.e., this study is the first time that their AML is treated). The study is divided into 2 parts, with different goals for each part. The primary objective of Part 1 is to determine the Part 2 Selected Dose of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in previously untreated CD123+ AML subjects who are ineligible for intensive chemotherapy. The primary objective of Part 2 is to evaluate the complete remission (CR) rate within the first 4 cycles of Tag in combination with Ven/Aza in previously untreated CD123+ AML subjects who are ineligible for intensive chemotherapy.
- Principal Investigator: Namrata Chandhok
- Study Phase: Phase II
- Enrollment Status: Not Accepting